The Good Brigade/DigitalVision via Getty Images Medical devices and supplies manufacturer Smith & Nephew (NYSE:SNN) (OTCPK:SNNUF) has had an underwhelming several years, but at its core is a well- positioned business in a business area with premium pricing and long-term growth prospects. My last piece on the name was September 2022’s Smith & Nephew: Still A Buy Despite Short-Term Challenges, rating it a buy. Since then, the shares have increased in price by 14%. I continue to think that the share price unde ...